Mol Biol Rep . Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms

[tetano]

Mol Biol Rep


. 2022 Mar 2.
doi: 10.1007/s11033-022-07132-7. Online ahead of print.
Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms


Ameneh Jafari ^{1 2} , Fahima Danesh Pouya ³ , Zahra Niknam ² , Meghdad Abdollahpour-Alitappeh ^{4 5} , Mostafa Rezaei-Tavirani ⁶ , Yousef Rasmi ^{3 7}



Affiliations

• PMID: 35235159
• DOI: 10.1007/s11033-022-07132-7

Abstract

The world is grappling with an unprecedented public health crisis COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2. Due to the high transmission/mortality rates and socioeconomic impacts of the COVID-19, its control is crucial. In the absence of specific treatment, vaccines represent the most efficient way to control and stop the pandemic. Many companies around the world are currently making efforts to develop the vaccine to combat COVID-19. This review outlines key strategies for generating SARS-CoV-2 vaccine candidates, along with the mechanism of action, advantages, and potential limitations of each vaccine. The use of nanomaterials and nanotechnology for COVID-19 vaccines development will also be discussed.

Keywords: COVID -19 vaccine platform; Nanoparticles-based vaccine; SARS-CoV-2; Vaccine candidate; Vaccine efficacy.